Hussam Farhoud, MD
Interventional Cardiology · Wichita, KSNPI 1144287574
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 33.3% of the total. Reporting peaked in 2019 at $6,751 and has fallen 78.4% since, to $1,461 in 2025.
Across 456 payments — averaging $54.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$8K
- Novartis$4K
- Boston Scientific$1K
- Abiomed$930
- Pfizer$413
- plus $2K from 20 others
Across 112 payments — averaging $2186.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$126K
- Boehringer Ingelheim Pharma GmbH & Co.kg$62K
- AstraZeneca$58K
- Amgen$5
What the payments were for
- Consulting fees$3,44414%
- Speaking & faculty fees$3,30013%
- Travel & lodging$5,96224%
- Food & beverage$11,93348%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 214 | $8,223 |
| Abbott | 59 | $7,764 |
| Novartis | 64 | $4,079 |
| Boston Scientific | 17 | $1,354 |
| Abiomed | 8 | $930 |
| Pfizer | 38 | $413 |
| AstraZeneca | 12 | $408 |
| E.r. Squibb & Sons, L.L.C. | 9 | $244 |
| Johnson & Johnson | 9 | $235 |
| Endologix LLC | 2 | $173 |
| Cvrx, Inc. | 2 | $161 |
| Tactile Systems Technology Inc | 1 | $154 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $121 |
| Amgen | 5 | $91 |
| Shockwave Medical, Inc | 1 | $84 |
| Impulse Dynamics (USA) Inc. | 1 | $58 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Cook Medical LLC | 1 | $24 |
| Merck | 1 | $22 |
| Biotronik Inc. | 1 | $21 |
| Bayer | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Surmodics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$3,300
- AVEIR$3,151
- Micra$2,251
- ALLURE QUADRA$1,425
- Accent Pacemaker$950
- Impella$752
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$713
- GENERAL VASCULAR ACCESS$466
- ALLURE$356
- WAINUA$250
- COREVALVE EVOLUT R$154
- FLEXITOUCH$154
- ACTITOUCH$154
- ENTRE$154
- Barostim Neo System$141
- WATCHMAN Access System$141
- COBALT DR MRI SURESCAN$128
- STINGRAY$126
- XARELTO$125
- CAMZYOS$125
How this compares
$24,674 in reported general payments places this provider in the 80th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 946 | $952,324 |
| EntrestoSacubitril/Valsartan | 347 | $442,194 |
| XareltoRivaroxaban | 344 | $333,832 |
| JardianceEmpagliflozin | 44 | $54,737 |
| MultaqDronedarone Hcl | 21 | $23,868 |
| BrilintaTicagrelor | 27 | $21,360 |
| Metoprolol Succinate | 1,554 | $20,309 |
| Carvedilol | 2,154 | $13,332 |
| CorlanorIvabradine Hcl | 15 | $13,061 |
| Losartan Potassium | 1,569 | $11,286 |
| Repatha SyringeEvolocumab | 16 | $10,675 |
| Repatha SureclickEvolocumab | 15 | $10,320 |
| Atorvastatin Calcium | 1,796 | $10,211 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 33 | $8,458 |
| ClopidogrelClopidogrel Bisulfate | 844 | $7,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $413 | $952,324946 claims |
| NovartisEntresto | $4,079 | $442,194347 claims |
| Johnson & JohnsonXarelto | $235 | $333,832344 claims |
| Sanofi-aventis U.S. LLCMultaq | $12 | $23,86821 claims |
| AstraZenecaBrilinta | $408 | $21,36027 claims |
| AmgenCorlanor | $91 | $13,06115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Wichita
- Maheedhar GedelaWichita$54K
- Christian HouraniWichita$17K
- Gaurav TyagiWichita$13K
- Ravi BajajWichita$10K
- Assem FarhatWichita$9K
- Venkata BoppanaWichita$9K
- Alaa BouladWichita$8K
- Rohma ShaikhWichita$4K
- George ReaderWichita$4K
- Mohamed ElmassryWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.